Navigation Links
Smith & Nephew Negative Pressure Wound Therapy Products To Be Available To Patients Through the Medicare Part B Competitive Bidding Process
Date:6/2/2008

out Smith & Nephew NPWT products, please visit our Web site at http://www.npwt.com

References:

1. Chariker ME, Jeter KF, Tintle TE, Ottsford JE. Effective management of incisional and cutaneous fistulae with closed suction wound draining. Contemp. Surg. 1989; 34:59-63

2. Campbell PE, Smith GS, Smith JM. Retrospective clinical evaluation of gauze-based negative pressure wound therapy. Int. Wound J. 2008; 5: 280-286

Enquiries

Investors

Liz Hewitt +44 (0)20 7401 7646

Group Director Corporate Affairs

Smith & Nephew

Media

Cindy Leggett-Flynn +1 (212) 333-3810

Robin Gilliland

Brunswick - New York

Jon Coles +44 (0) 20 7404 5959

Justine McIlroy

Brunswick - London

About Smith & Nephew

Smith & Nephew is a global medical technology business, specializing in Orthopedic Reconstruction, Orthopedic Trauma and Clinical Therapies, Endoscopy and Advanced Wound Management products. Smith & Nephew is a global leader in arthroscopy and advanced wound management and is one of the leading global orthopedics companies.

Smith & Nephew is dedicated to helping improve people's lives. The Company prides itself on the strength of its relationships with its surgeons and professional healthcare customers, with whom its name is synonymous with high standards of performance, innovation and trust. The Company operates in 32 countries around the world. Annual sales in 2007 were $3.4 billion.

Forward-Looking Statements

This press release contains certain "forward-looking statements" within the meaning of the US Private Securities Litigation Reform Act of 1995. In particular, statements regarding expected revenue growth and trading margins are forward-looking statements as are discussions of our product pipeline. These statements, as well as the phrases "aim", "plan", "intend", "anticipate", "well-placed", "belie
'/>"/>

SOURCE Smith & Nephew
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Amira Pharmaceuticals Achieves Milestones in FLAP Inhibitor Program With GlaxoSmithKline
2. Emerging Combination Therapies, Including Drugs from Novartis/Schering-Plough and GlaxoSmithKline/Theravance Will Drive the COPD Drug Market to More Than $11 Billion in 2017
3. Video: GlaxoSmithKline Consumer Healthcare Offers Free Nicotine Lozenges for All Certified Pilots and Air Traffic Controllers to Help Them Safely Quit Smoking
4. GlaxoSmithKline Announces $500,000 in Fellowships at Stanford Graduate School of Business
5. SmithAmundsen Elects New Partner, Linda F. Newman
6. Law Offices of Howard G. Smith Announces 24 Days Remaining to Move to Be a Lead Plaintiff in the Shareholder Lawsuit Against Inverness Medical Innovations, Inc.
7. IADR and GlaxoSmithKline Consumer Healthcare announce winners
8. A Statement from GlaxoSmithKline Consumer Healthcare on 2008 Update to the U.S. Public Health Service Guideline on Treating Tobacco Use and Dependence
9. Smith & Nephew Endoscopy Launches the FOOTPRINT PK Suture Anchor for Shoulder Repair
10. Concern From Doctors Regarding the Cardiovascular Safety of GlaxoSmithKlines Avandia Increases Nine-Fold Following Publication of Meta-Analysis
11. Law Offices of Howard G. Smith Announces 21 Days Remaining to Move to Be a Lead Plaintiff in the Shareholder Lawsuit Against Vertex Pharmaceuticals Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2014)... Hospital Pediatrician-in-Chief Jon McCullers, MD, was recently invited ... of Nature Reviews Microbiology , one of ... a world-renowned infectious disease specialist, and chair of ... Tennessee Health Science Center, analyzed the epidemiology and ... 1968 pandemics, as well as more recent 2009 ...
(Date:4/17/2014)... cause of neuronal death in Parkinson,s disease is still ... be mistaken for foreign invaders and killed by the ... diseases like type I diabetes, celiac disease, and multiple ... April 16, 2014, in Nature Communications . , ... Parkinson,s disease; but if true, it could lead to ...
(Date:4/17/2014)... An international team led by researchers at UC Davis ... plays a key role in cell division, also boosts ... the first time the complex has been shown to ... B1/Cdk1 an excellent target to control cellular energy production, ... was published online today in the journal Developmental ...
(Date:4/17/2014)... 2014 Meaningful long-term survival is possible for ... abdomen when treated with cytoreductive surgery with Hyperthermic ... analysis by physicians at Wake Forest Baptist Medical ... reported, single-center experience with cytoreductive surgery and HIPEC, ... analysis of 20 years, worth of patient data ...
(Date:4/17/2014)... adrenaline after they suffer a cardiac arrest outside of ... long-term, according to new research conducted at St. Michael,s ... a cardiac arrest get adrenaline, which has been the ... Dr. Steve Lin, an emergency physician and trauma team ... treatment, long-term survival rates of patients who suffer a ...
Breaking Medicine News(10 mins):Health News:Is Parkinson's an autoimmune disease? 2Health News:Dual role: Key cell division proteins also power up mitochondria 2Health News:20 years of data shows treatment technique improvement for advanced abdominal cancer 2Health News:Adrenaline does little to increase patient's survival after cardiac arrest 2
... ... a David versus Goliath struggle raging in the West, joins the stellar line-up ... York City and in Los Angeles (August 7 - 13). The film will ... the Reel Impact series on Planet Green, a network of Discovery Communications.,Split Estate ...
... , , , ... (Nasdaq: CLRT ), a premier anatomic pathology and molecular ... financial results for the second quarter and six months ended June 30, ... the second quarter of 2009 versus the second quarter of 2008, and ...
... , EAST RUTHERFORD, N.J., Aug. 4 Cambrex Corporation ... 30, 2009. , , Highlights , , ... impact of foreign currency. Reported sales declined by 9.8% for the quarter. , ... in the same quarter last year (see attached table). , ...
... ON, Aug. 4 /PRNewswire-FirstCall/ - Covidien (NYSE: COV ... Nuvo Research Inc. (TSX:NRI), a Canadian drug development company, ... (FDA) has set a new action date under the ... sodium) topical solution 1.5% w/w of November 4, 2009. ...
... , WALTHAM, Mass., Aug. 4 Inverness ... leader in enabling individuals to take charge of their health ... management, today announced that it intends to offer $150 million ... of the notes will be guaranteed by certain of Inverness, ...
... delivery was vaginal or C-section doesn,t matter, study finds ... anesthesia during a Cesarean delivery doesn,t increase the risk ... , "We found that the incidence of learning disabilities ... those who were delivered via C-section but with general ...
Cached Medicine News:Health News:Premier of Split Estate at DocuWeeks 2009 to Call National Attention to Urban Drilling in New York and Los Angeles 2Health News:Premier of Split Estate at DocuWeeks 2009 to Call National Attention to Urban Drilling in New York and Los Angeles 3Health News:Clarient Reports Second Quarter Revenue Up 40 Percent 2Health News:Clarient Reports Second Quarter Revenue Up 40 Percent 3Health News:Clarient Reports Second Quarter Revenue Up 40 Percent 4Health News:Clarient Reports Second Quarter Revenue Up 40 Percent 5Health News:Clarient Reports Second Quarter Revenue Up 40 Percent 6Health News:Clarient Reports Second Quarter Revenue Up 40 Percent 7Health News:Clarient Reports Second Quarter Revenue Up 40 Percent 8Health News:Clarient Reports Second Quarter Revenue Up 40 Percent 9Health News:Clarient Reports Second Quarter Revenue Up 40 Percent 10Health News:Cambrex Reports Second Quarter 2009 Results 2Health News:Cambrex Reports Second Quarter 2009 Results 3Health News:Cambrex Reports Second Quarter 2009 Results 4Health News:Cambrex Reports Second Quarter 2009 Results 5Health News:Cambrex Reports Second Quarter 2009 Results 6Health News:Cambrex Reports Second Quarter 2009 Results 7Health News:Cambrex Reports Second Quarter 2009 Results 8Health News:Cambrex Reports Second Quarter 2009 Results 9Health News:Cambrex Reports Second Quarter 2009 Results 10Health News:Cambrex Reports Second Quarter 2009 Results 11Health News:Cambrex Reports Second Quarter 2009 Results 12Health News:FDA extends review of Pennsaid(R) diclofenac sodium topical solution 2Health News:FDA extends review of Pennsaid(R) diclofenac sodium topical solution 3Health News:Inverness Medical Innovations, Inc. Announces Offering of $150 Million of Senior Notes 2Health News:No Link Found Between Birth Anesthesia and Learning Issues 2
(Date:1/15/2014)... 15, 2014 AARP Foundation today announced it has established ... from the severe cold weather that has gripped much of ... those in need; so to support these emergency relief efforts ... $250,000, which could mean up to $500,000 in aid. The ...
(Date:1/15/2014)... , Jan. 15, 2014  Humberto C. Antunes,  Galderma  ... Award" from the Journal of Drugs in Dermatology ... Clinical Conference (ODAC). The event is January 17-20, 2014, at the ... . The ODAC is a ...
(Date:1/15/2014)... MultiCell Technologies, Inc. (OTC Bulletin Board: MCET.OB ... composition of matter, biological targets, mechanism of action, methods ... This patent application describes a novel class ... which interfere with the basic homeostatic cellular processes in ...
Breaking Medicine Technology:AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 2AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3
... , , , WINNIPEG, ... rejected a plan to allow the wholesale reimportation of cheaper ... the drug industry and secure cheaper prescription for Americans. ... for drugs than people in Canada, Australia, the UK, New ...
... Orexigen(R) Therapeutics, Inc. (Nasdaq: OREX ), a biopharmaceutical ... on December 23, 2009 the Compensation Committee of the Company,s ... to purchase a total of 64,000 shares of common stock ... are intended to be incentive stock options to the extent ...
Cached Medicine Technology:Obama Plan Buckles Under Pharma Lobby; Plan to Import Low-Cost Medicines Derails 2Obama Plan Buckles Under Pharma Lobby; Plan to Import Low-Cost Medicines Derails 3Orexigen(R) Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635 2Orexigen(R) Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: